IP Library Granted Patent US 7,338,934
Granted Patent B2
US 7,338,934 · App. 10/787,879 · Granted Mar 4, 2008

Fibroblast growth factor-14

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,338,934
App. No.
10/787,879
Granted
Mar 4, 2008
Kind
B2
Abstract

Disclosed is a human Fibroblast growth factor-14 polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for promoting wound healing for example as a result of burns and ulcers, to prevent neuronal damage due to associated with stroke and promote neuronal growth, and to prevent skin aging and hair loss, to stimulate angiogenesis, mesodermal induction in early embryos and limb regeneration. Antagonists against such polypeptides and their use as a therapeutic to prevent abnormal cellular proliferation, hyper-vascular diseases and epithelial lens cell proliferation are also disclosed. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.

Claims (20)

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) amino acid residues 1 to 225 of SEQ ID NO:2; and

(b) amino acid residues 27 to 225 of SEQ ID NO:2.

2. The polypeptide of claim 1 which comprises amino acid sequence (a).

3. The polypeptide of claim 1 which comprises amino acid sequence (b).

4. The polypeptide of claim 1 wherein said polypeptide consists of amino acid residues 27 to 225 of SEQ ID NO:2.

5. The polypeptide of claim 1 which further comprises a heterologous amino acid sequence selected from the group consisting of:

(a) a leader sequence, wherein said leader sequence is capable of directing secretion; and

(b) an N-terminal identification peptide.

6. A composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier.

7. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full length polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-974; and

(b) the amino acid sequence of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-974.

8. The polypeptide of claim 7 which comprises amino acid sequence (a).

9. The polypeptide of claim 7 which comprises amino acid sequence (b).

10. The polypeptide of claim 7 wherein said polypeptide consists of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-974.

11. The polypeptide of claim 7 which further comprises a heterologous amino acid sequence selected from the group consisting of:

(a) a leader sequence, wherein said leader sequence is capable of directing secretion; and

(b) an N-terminal identification peptide.

12. A composition comprising the isolated polypeptide of claim 7 and a pharmaceutically acceptable carrier.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT TO RE-RECORD ASSIGNMENT PREVIOUSLY RECORDED ON REEL 015369 FRAME 0141. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE FROM INFINEON TECHNOLOGIES AG TO HUMAN GENOME SCIENCES, INC.. Recorded Nov 18, 2004
From: INFINEON TECHNOLOGIES AG
To: HUMAN GENOME SCIENCES, INC.
Reel/Frame 015373/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2004
From: INFINEON TECHNOLOGIES NORTH AMERICA CORP.
To: INFINEON TECHNOLOGIES AG
Reel/Frame 015369/0141 →